Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 18, 2018 - Issue 7
Submit an article Journal homepage
1,135
Views
6
CrossRef citations to date
0
Altmetric
Drug Evaluation

CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine

Marco TagliamentoLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, ItalyView further author information
,
Erika RijavecLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, ItalyView further author information
,
Giulia BarlettaLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, ItalyView further author information
,
Federica BielloLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, ItalyView further author information
,
Giovanni RossiLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, ItalyView further author information
,
Francesco GrossiLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, ItalyCorrespondence[email protected]
View further author information
&
Carlo GenovaLung Cancer Unit, Ospedale Policlinico San Martino, Genoa, Italy;Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, ItalyORCID Iconhttp://orcid.org/0000-0003-3690-8582View further author information
ORCID Icon show all
Pages 829-835 | Received 28 Jan 2018, Accepted 20 Jun 2018, Published online: 04 Jul 2018

References

  • Lung and Bronchus Cancer - Cancer Stat Facts [Internet]. [ cited 2017 Dec 28]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html.
  • Socola F, Scherfenberg N, Raez LE. Therapeutic vaccines in non-small cell lung cancer. ImmunoTargets Ther. 2013;2:115–124.
  • Baxter D. Active and passive immunization for cancer. Hum Vaccines Immunother. 2014;10:2123–2129.
  • Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2006;1:93–104.
  • González G, Lage A, Crombet T, et al. CIMAvax-EGF: a novel therapeutic vaccine for advanced lung cancer. Biotecnol. Apl. 2009;26:345–348.
  • Crombet Ramos T, Rodríguez PC, Neninger Vinageras E, et al. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14:1303–1311.
  • Rodríguez PC, Rodríguez G, González G, et al. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 2010;12:17–23.
  • Saavedra D, Crombet T. CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol Internet2017. cited 2018 May 16; 8Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346887/.
  • Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102:37–46.
  • González G, Crombet T, Catalá M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol Off J Eur Soc Med Oncol. 1998;9:431–435.
  • Gonzalez G, Crombet T, Torres F, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol Off J Eur Soc Med Oncol. 2003;14:461–466.
  • Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol Baltim Md. 1950;1982(128):2453–2457.
  • Ramos TC, Vinageras EN, Ferrer MC, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther. 2006;5:145–149.
  • Neninger E, Verdecia BG, Crombet T, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother Hagerstown Md. 1997;2009(32):92–99.
  • Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:1452–1458.
  • Rodriguez PC, Popa X, Martínez O, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:3782–3790.
  • Hernandez M, Ortiz RA, Neninger E, et al. P2. 40: CIMAvaxEGF vaccine for the treatment of real-world NSCLC patients. J Thorac Oncol. 2016;11:S242.
  • Macias AE, Ortiz R, Santiesteban E, et al. P2.34: vaxira and CIMAvax-EGF therapeutic vaccines combination in the advanced NSCLC treatment. J Thorac Oncol. 2016;11:S236–S237.
  • 60PAntitumor effects of EGF-pathway immunization in NSCLC | Annals of Oncology | Oxford Academic [Internet]. [ cited 2018 May 16]. Available from: https://academic.oup.com/annonc/article/28/suppl_11/mdx711.041/4726856.
  • Rosell R, Neninger E, Nicolson M, et al. Pathway targeted immunotherapy: rationale and evidence of durable clinical responses with a novel, EGF-directed agent for advanced NSCLC. J Thorac Oncol. 2016;11:1954–1961.
  • Karachaliou N, Zorrilla AC, Rodríguez-Abreu D, et al. 198TiP Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: the EPICAL study. J Thorac Oncol. 2018;13:S118–S119.
  • Kelly RJ, Giaccone G. Lung Cancer Vaccines: Cancer J. 2011;17:302–308.
  • Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non–small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–3807.
  • Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:2787–2799.
  • Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2017;15:504–535.
  • Hirsch F, Genova C. Clinical potential of necitumumab in non-small cell lung carcinoma. OncoTargets Ther. 2016;9:5427–5437.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.